Adhera Therapeutics IncOTC Pink - Limited Information:ATRX
- LAST PRICE0.0060
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0064 / 0.0060
- Day Range
- 52 Week Range
- Volume72,661
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATRX |
|---|---|---|
| 02:40 ET | 8600 | 0.0064 |
| 03:14 ET | 64040 | 0.006 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adhera Therapeutics Inc | 43.3K | 0.0x | --- |
Vioquest Pharmaceuticals Inc | 43.1K | 0.0x | --- |
Scopus Biopharma Inc | 67.3K | 0.0x | --- |
Amarantus Bioscience Holdings Inc | 63.1K | 0.0x | --- |
Immunotech Laboratories Inc | 57.5K | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Company Information
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Company’s behalf and under its direct supervision.
Contact Information
- Headquarters
- P.O. Box 2161WAKE FOREST, NC, United States 27588
- Phone
- 919-578-5901
- Fax
- 302-674-5266
Executives
- Vice Chairman of the Board, Acting Chief Financial Officer, Chief Operating Officer, Chief Business Officer
- Andrew Kucharchuk
- Independent Director
- Charles Rice
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.3K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 7.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.06 |
EPS | $-1.12 |
Book Value | $-7.03 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
